External broker reports(aggregated public sources), Axis Direct

Axis Direct

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only.  Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

Dr. Reddy's Laboratories / Equity Bottom-Up

<ul><li>The US business reported sales of $391Mn (-3.0% QoQ), led by a lower base business of ~$245 Mn QoQ, gRevlimid ~$115 Mn QoQ, and acquisition business of $30-$35 Mn QoQ.</li><li>Ex-gRevlimid base business is impacted by higher price erosion and low volume offtake seasonally.</li><li>Major molecules like gSuboxone, gVascepa, gCiprodex, and gToprol are showing slightly low volume MS on a sequential business. </li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

The US business reported sales of $391Mn (-3.0% QoQ), led by a lower base business of ~$245 Mn QoQ, gRevlimid ~$115 Mn QoQ, and acquisition business of $30-$35 Mn QoQ.Ex-gRevlimid base business is impacted by higher price erosion and low volume offtake seasonally.Major molecules like gSuboxone, gVascepa, gCiprodex, and gToprol are showing slightly low volume MS on a sequential business. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Dr Reddy’s Laboratories Ltd - GRevlimid Revenue Topped Out